#72Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
This article highlights that physician authorization of medical cannabis does not mitigate the risk of Cannabis Use Disorder development, requiring clinicians to implement structured monitoring protocols and dose management strategies similar to other controlled substances. Understanding this distinction is critical for establishing appropriate baseline assessments, tracking usage patterns, and identifying early signs of problematic use in patients who may otherwise assume their prescriptions carry inherent safety guarantees.
This article emphasizes that physician recommendation or formal diagnosis does not mitigate the risk of Cannabis Use Disorder (CUD) in medical cannabis patients. Cannabis Use Disorder, defined by continued use despite adverse consequences, affects an estimated 9% to 33% of users depending on frequency of use, with daily users at highest risk. The medicalization of cannabis may paradoxically increase CUD risk by reducing patients’ perception of harm and facilitating escalating use patterns. The authors stress that physicians prescribing medical cannabis should establish clear protocols regarding dosing frequency and maintain ongoing dialogue with patients to monitor for signs of problematic use. Regular screening for CUD symptoms and explicit counseling about addiction risk are indicated as part of responsible medical cannabis prescribing. Clinicians should recognize that medical authorization alone does not guarantee safe use and requires active patient monitoring and communication to prevent the development of cannabis dependence.
“The reality is that medical authorization doesn’t confer immunity from Cannabis Use Disorder, and I see patients regularly who believed their prescription exempted them from dependency risks. We need honest conversations about dosing frequency and individual vulnerability factors before and during treatment, because the therapeutic window and the addiction threshold aren’t the same for everyone.”
🏥 While medical cannabis prescriptions may provide symptomatic relief for certain conditions, clinicians should recognize that formal authorization does not protect patients from developing Cannabis Use Disorder, a condition defined by compulsive use despite adverse consequences. The evidence base for cannabis dosing and duration remains limited compared to conventional pharmaceuticals, making it difficult to establish clear safety thresholds, and individual vulnerability to dependence varies based on genetic factors, concurrent substance use, psychiatric history, and age at initiation. Additionally, some patients may rationalize escalating use by framing it within a medical context, potentially delaying recognition of problematic patterns. To mitigate these risks, prescribing physicians should establish baseline frequency and dosage parameters, conduct regular follow-up assessments specifically screening for signs of misuse or tolerance escalation, and maintain open discussions about the distinction between therapeutic benefit and compulsive use patterns.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: